Physician profile
Michael Epstein
NPI 1942238928
$162,082.00
in general payments reported to CMS, 2019-2025
46 companies · $88.59 in 2025
The $88.59 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $31K · 2021: $40K · 2022: $26K · 2023: $3,182 · 2025: $88.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,875 · Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,875.00 |
| Food and Beverage | $1,395.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $57,810.00 | 2019-2021 | |
| Amgen INC. | $33,479.82 | 2020-2023 | Avsola, Amjevita |
| Pfizer INC. | $25,449.70 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $12,077.68 | 2021-2022 | |
| Redhill Biopharma INC. | $10,319.78 | 2020-2022 | |
| Daiichi Sankyo INC. | $3,806.32 | 2019-2023 | Injectafer |
| Celgene Corporation | $3,626.83 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $2,751.06 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,698.62 | 2019-2023 | Xifaxan, Relistor |
| Abbvie INC. | $2,409.89 | 2019-2023 | |
| Ardelyx, INC. | $2,160.24 | 2022-2023 | Ibsrela |
| Pharmacosmos Therapeutics INC. | $1,499.54 | 2021-2023 | Monoferric |
| Janssen Biotech, INC. | $824.32 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $672.04 | 2019-2023 | Entyvio, Gattex |
| Merck Sharp & Dohme LLC | $361.79 | 2019-2023 | Dificid, Zinplava |
Show all 43 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.